ArticleProceedings of the National Academy of Sciences of the United States of America2021
On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 473 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
473 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Meta-Analysis and Machine Learning Prediction of Protein Corona Composition across Nanoparticle Systems in Biological Media.ACS nano · 2025Pooled it
- Non-Viral CRISPR carriers: transient delivery with lasting effects.Drug delivery · 2026Review
- Human T cell engineering via serial delivery of mRNA encapsulated within lipid nanoparticles.Molecular therapy. Nucleic acids · 2026Article
- Cas12a chRDNA-mediatedMolecular therapy. Nucleic acids · 2026Article
- Surface charge of LNP and V-ATPase activity of target cell synergize in functional delivery of nucleic acidInternational journal of pharmaceutics: X · 2026Article
- Engineering lipid nanoparticle surface hydrophobicity to modulate nano-bio interface and enable tissue-selective mRNA delivery.Biomaterials · 2026Article
- The advances and challenges of mRNA-LNP application in fields of hematology and oncology therapeutics.Journal of hematology & oncology · 2026Review
- Cancer nanomedicine and RNA/Lipid nanoparticle platforms in oncology: developmental evolution, translational barriers, and precision-therapy opportunities.Journal of the Egyptian National Cancer Institute · 2026Review
- Visualizing Metabolism: Lipid-Based Raman Nanoreporters as an Enabling Platform for Metabolic Imaging and Precision Medicine.ACS nano medicine · 2026Review
- In vivo engineering of CAR natural killer cells for immunotherapy using ligand-directed lipid nanoparticles.Nature biotechnology · 2026Article
- PEG-associated efficacy loss in lipid nanoparticles persists across formulation modifications for mRNA delivery.Drug delivery and translational research · 2026Article
- Optimization of lipid nanoparticles reduces hepatic accumulation and enhances local delivery of mRNA.Science China. Life sciences · 2026Article
- Mechanisms and determinants of mRNALipid Nanoparticle biodistribution: From pharmacokinetics to clinical translation.Bioengineering & translational medicine · 2026Review
- Receptor discovery for nanomaterial soft and hard coronas via a biosensor-based Fishing strategy.Nature protocols · 2026Review
- Chemical and Biological Determinants of PEG-Lipid Shedding From Therapeutic Nanoparticles.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Overcoming hepatic tropism: Precision engineering of lipid nanoparticles for extrahepatic RNA delivery.Materials today. Bio · 2026Review
- Integrating delivery systems and microenvironmental cues to accelerate clinical translation of cardiac reprogramming.Materials today. Bio · 2026Review
- Bioactive lipid-derived nanoparticles for RNA delivery.Materials today (Kidlington, England) · 2026Article
- Structural evolution of ionizable lipids for nucleic acid delivery.Nature reviews. Chemistry · 2026Review
- mRNA lipid nanoparticle vaccines: current status, challenges and future prospects.Molecular biomedicine · 2026Review
413 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Lipid nanoparticles (LNPs) are a clinically mature technology for the delivery of genetic medicines but have limited therapeutic applications due to liver accumulation. Recently, our laboratory developed selective organ targeting (SORT) nanoparticles that expand the therapeutic applications of genetic medicines by enabling delivery of messenger RNA (mRNA) and gene editing systems to non-liver tissues. SORT nanoparticles include a supplemental SORT molecule whose chemical structure determines the LNP's tissue-specific activity. To understand how SORT nanoparticles surpass the delivery barrier of liver hepatocyte accumulation, we studied the mechanistic factors which define their organ-targeting properties. We discovered that the chemical nature of the added SORT molecule controlled biodistribution, global/apparent pK
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.